Loading…
Clearance of moxifloxacin during continuous haemofiltration (CVVHF) in vitro
Background/aims: The clearance of moxifloxacin is reported to be unaltered in the presence of renal insufficiency. There is little information about the clearance of intravenous moxifloxacin in renal replacement therapies during intensive care. The aim of this study was to determine the clearance of...
Saved in:
Published in: | Journal of antimicrobial chemotherapy 2005-08, Vol.56 (2), p.360-364 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c416t-5a6c62e01b17fb6e4e9d21252fc12f1ac36a97e9a621bf2d439af28df255c1963 |
---|---|
cites | cdi_FETCH-LOGICAL-c416t-5a6c62e01b17fb6e4e9d21252fc12f1ac36a97e9a621bf2d439af28df255c1963 |
container_end_page | 364 |
container_issue | 2 |
container_start_page | 360 |
container_title | Journal of antimicrobial chemotherapy |
container_volume | 56 |
creator | Ittner, K. P. Roth, G. Gruber, M. Pawlik, M. Taeger, K. |
description | Background/aims: The clearance of moxifloxacin is reported to be unaltered in the presence of renal insufficiency. There is little information about the clearance of intravenous moxifloxacin in renal replacement therapies during intensive care. The aim of this study was to determine the clearance of moxifloxacin during continuous veno-venous haemofiltration (CVVHF) in vitro. Methods: The elimination of moxifloxacin (reservoir with 600 mL of washed human erythrocytes, 100 mL of NaHCO3 and various amounts of Ringer solution and human albumin to give a total volume of 1000 mL, pH 7.35 ± 0.5; haematocrit 41 ± 2) during CVVHF in vitro with two filter conditions (during priming, after priming), three protein concentrations (human albumin: 0 g/L, 20 g/L, 40 g/L) and two filtration velocities [(i) standard condition: blood flow at 100 mL/min and turnover of 2 L/h; (ii) blood flow at 50 mL/min and turnover of 1 L/h] were investigated. Results: A new filter needs 20 min of priming before moxifloxacin reaches a steady relative filtration rate. The sieving coefficient with 0 g/L albumin was 1.07, with 20 g/L 0.90 and with 40 g/L 0.80. Under standard filtration conditions (i) the renal clearance was between 26.7 and 35.7 mL/min, and under the altered conditions (ii) it was 15.2 mL/min. Conclusion: During CVVHF in vitro we found filtration clearances of moxifloxacin of the same order as its renal clearance in healthy subjects. The high sieving coefficient, nearly independent of blood protein concentration, would suggest that moxifloxacin is filtered almost as freely as creatinine. These results do not indicate a need for dose adjustment under appropriate haemofiltration conditions and normal hepatic function. |
doi_str_mv | 10.1093/jac/dki205 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68431152</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>886212371</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-5a6c62e01b17fb6e4e9d21252fc12f1ac36a97e9a621bf2d439af28df255c1963</originalsourceid><addsrcrecordid>eNpd0N9LHDEQwPFQKvW0fekfUBahRYWtmWSTvTyW88dZrvRFRXwJc9mk5tzd2GRXrv-9kTsU-jQP82EYvoR8BvodqOInKzQnzYNnVLwjE6gkLRlV8J5MKKeirCvBd8leSitKqRRy-oHsglBTTpmYkMWstRixN7YIrujC2rs2rNH4vmjG6Ps_hQn94PsxjKm4R9sF59sh4uBDXxzObm7m50dFxk9-iOEj2XHYJvtpO_fJ9fnZ1WxeLn5fXM5-LEpTgRxKgdJIZiksoXZLaSurGgZMMGeAOUDDJaraKpQMlo41FVfo2LRxTAgDSvJ98m1z9zGGv6NNg-58MrZtsbf5Ty2nFQcQLMOD_-AqjLHPv2kGtZRK0Sqj4w0yMaQUrdOP0XcY_2mg-iWwzoH1JnDGX7YXx2Vnmze6LZrB1y3AZLB1L219enMyu1rR7MqN82mw69c9xgcta14LPb-906cXpz_ru1-3mvFn5zCSfg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217669904</pqid></control><display><type>article</type><title>Clearance of moxifloxacin during continuous haemofiltration (CVVHF) in vitro</title><source>Oxford Journals Online</source><creator>Ittner, K. P. ; Roth, G. ; Gruber, M. ; Pawlik, M. ; Taeger, K.</creator><creatorcontrib>Ittner, K. P. ; Roth, G. ; Gruber, M. ; Pawlik, M. ; Taeger, K.</creatorcontrib><description>Background/aims: The clearance of moxifloxacin is reported to be unaltered in the presence of renal insufficiency. There is little information about the clearance of intravenous moxifloxacin in renal replacement therapies during intensive care. The aim of this study was to determine the clearance of moxifloxacin during continuous veno-venous haemofiltration (CVVHF) in vitro. Methods: The elimination of moxifloxacin (reservoir with 600 mL of washed human erythrocytes, 100 mL of NaHCO3 and various amounts of Ringer solution and human albumin to give a total volume of 1000 mL, pH 7.35 ± 0.5; haematocrit 41 ± 2) during CVVHF in vitro with two filter conditions (during priming, after priming), three protein concentrations (human albumin: 0 g/L, 20 g/L, 40 g/L) and two filtration velocities [(i) standard condition: blood flow at 100 mL/min and turnover of 2 L/h; (ii) blood flow at 50 mL/min and turnover of 1 L/h] were investigated. Results: A new filter needs 20 min of priming before moxifloxacin reaches a steady relative filtration rate. The sieving coefficient with 0 g/L albumin was 1.07, with 20 g/L 0.90 and with 40 g/L 0.80. Under standard filtration conditions (i) the renal clearance was between 26.7 and 35.7 mL/min, and under the altered conditions (ii) it was 15.2 mL/min. Conclusion: During CVVHF in vitro we found filtration clearances of moxifloxacin of the same order as its renal clearance in healthy subjects. The high sieving coefficient, nearly independent of blood protein concentration, would suggest that moxifloxacin is filtered almost as freely as creatinine. These results do not indicate a need for dose adjustment under appropriate haemofiltration conditions and normal hepatic function.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dki205</identifier><identifier>PMID: 15983025</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Anti-Bacterial Agents - blood ; Anti-Bacterial Agents - pharmacokinetics ; antibiotics ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Area Under Curve ; artificial membranes ; Aza Compounds - blood ; Aza Compounds - pharmacokinetics ; Biological and medical sciences ; Culture Media ; dosage recommendations ; Erythrocytes - metabolism ; Fluoroquinolones ; Hemofiltration ; Humans ; In Vitro Techniques ; Medical sciences ; Metabolic Clearance Rate ; Models, Biological ; Pharmacology. Drug treatments ; Quinolines - blood ; Quinolines - pharmacokinetics ; renal failure ; renal replacement therapy</subject><ispartof>Journal of antimicrobial chemotherapy, 2005-08, Vol.56 (2), p.360-364</ispartof><rights>2005 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Aug 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-5a6c62e01b17fb6e4e9d21252fc12f1ac36a97e9a621bf2d439af28df255c1963</citedby><cites>FETCH-LOGICAL-c416t-5a6c62e01b17fb6e4e9d21252fc12f1ac36a97e9a621bf2d439af28df255c1963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16983790$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15983025$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ittner, K. P.</creatorcontrib><creatorcontrib>Roth, G.</creatorcontrib><creatorcontrib>Gruber, M.</creatorcontrib><creatorcontrib>Pawlik, M.</creatorcontrib><creatorcontrib>Taeger, K.</creatorcontrib><title>Clearance of moxifloxacin during continuous haemofiltration (CVVHF) in vitro</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J. Antimicrob. Chemother</addtitle><description>Background/aims: The clearance of moxifloxacin is reported to be unaltered in the presence of renal insufficiency. There is little information about the clearance of intravenous moxifloxacin in renal replacement therapies during intensive care. The aim of this study was to determine the clearance of moxifloxacin during continuous veno-venous haemofiltration (CVVHF) in vitro. Methods: The elimination of moxifloxacin (reservoir with 600 mL of washed human erythrocytes, 100 mL of NaHCO3 and various amounts of Ringer solution and human albumin to give a total volume of 1000 mL, pH 7.35 ± 0.5; haematocrit 41 ± 2) during CVVHF in vitro with two filter conditions (during priming, after priming), three protein concentrations (human albumin: 0 g/L, 20 g/L, 40 g/L) and two filtration velocities [(i) standard condition: blood flow at 100 mL/min and turnover of 2 L/h; (ii) blood flow at 50 mL/min and turnover of 1 L/h] were investigated. Results: A new filter needs 20 min of priming before moxifloxacin reaches a steady relative filtration rate. The sieving coefficient with 0 g/L albumin was 1.07, with 20 g/L 0.90 and with 40 g/L 0.80. Under standard filtration conditions (i) the renal clearance was between 26.7 and 35.7 mL/min, and under the altered conditions (ii) it was 15.2 mL/min. Conclusion: During CVVHF in vitro we found filtration clearances of moxifloxacin of the same order as its renal clearance in healthy subjects. The high sieving coefficient, nearly independent of blood protein concentration, would suggest that moxifloxacin is filtered almost as freely as creatinine. These results do not indicate a need for dose adjustment under appropriate haemofiltration conditions and normal hepatic function.</description><subject>Anti-Bacterial Agents - blood</subject><subject>Anti-Bacterial Agents - pharmacokinetics</subject><subject>antibiotics</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Area Under Curve</subject><subject>artificial membranes</subject><subject>Aza Compounds - blood</subject><subject>Aza Compounds - pharmacokinetics</subject><subject>Biological and medical sciences</subject><subject>Culture Media</subject><subject>dosage recommendations</subject><subject>Erythrocytes - metabolism</subject><subject>Fluoroquinolones</subject><subject>Hemofiltration</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Medical sciences</subject><subject>Metabolic Clearance Rate</subject><subject>Models, Biological</subject><subject>Pharmacology. Drug treatments</subject><subject>Quinolines - blood</subject><subject>Quinolines - pharmacokinetics</subject><subject>renal failure</subject><subject>renal replacement therapy</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNpd0N9LHDEQwPFQKvW0fekfUBahRYWtmWSTvTyW88dZrvRFRXwJc9mk5tzd2GRXrv-9kTsU-jQP82EYvoR8BvodqOInKzQnzYNnVLwjE6gkLRlV8J5MKKeirCvBd8leSitKqRRy-oHsglBTTpmYkMWstRixN7YIrujC2rs2rNH4vmjG6Ps_hQn94PsxjKm4R9sF59sh4uBDXxzObm7m50dFxk9-iOEj2XHYJvtpO_fJ9fnZ1WxeLn5fXM5-LEpTgRxKgdJIZiksoXZLaSurGgZMMGeAOUDDJaraKpQMlo41FVfo2LRxTAgDSvJ98m1z9zGGv6NNg-58MrZtsbf5Ty2nFQcQLMOD_-AqjLHPv2kGtZRK0Sqj4w0yMaQUrdOP0XcY_2mg-iWwzoH1JnDGX7YXx2Vnmze6LZrB1y3AZLB1L219enMyu1rR7MqN82mw69c9xgcta14LPb-906cXpz_ru1-3mvFn5zCSfg</recordid><startdate>20050801</startdate><enddate>20050801</enddate><creator>Ittner, K. P.</creator><creator>Roth, G.</creator><creator>Gruber, M.</creator><creator>Pawlik, M.</creator><creator>Taeger, K.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20050801</creationdate><title>Clearance of moxifloxacin during continuous haemofiltration (CVVHF) in vitro</title><author>Ittner, K. P. ; Roth, G. ; Gruber, M. ; Pawlik, M. ; Taeger, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-5a6c62e01b17fb6e4e9d21252fc12f1ac36a97e9a621bf2d439af28df255c1963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Anti-Bacterial Agents - blood</topic><topic>Anti-Bacterial Agents - pharmacokinetics</topic><topic>antibiotics</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Area Under Curve</topic><topic>artificial membranes</topic><topic>Aza Compounds - blood</topic><topic>Aza Compounds - pharmacokinetics</topic><topic>Biological and medical sciences</topic><topic>Culture Media</topic><topic>dosage recommendations</topic><topic>Erythrocytes - metabolism</topic><topic>Fluoroquinolones</topic><topic>Hemofiltration</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Medical sciences</topic><topic>Metabolic Clearance Rate</topic><topic>Models, Biological</topic><topic>Pharmacology. Drug treatments</topic><topic>Quinolines - blood</topic><topic>Quinolines - pharmacokinetics</topic><topic>renal failure</topic><topic>renal replacement therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ittner, K. P.</creatorcontrib><creatorcontrib>Roth, G.</creatorcontrib><creatorcontrib>Gruber, M.</creatorcontrib><creatorcontrib>Pawlik, M.</creatorcontrib><creatorcontrib>Taeger, K.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ittner, K. P.</au><au>Roth, G.</au><au>Gruber, M.</au><au>Pawlik, M.</au><au>Taeger, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clearance of moxifloxacin during continuous haemofiltration (CVVHF) in vitro</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J. Antimicrob. Chemother</addtitle><date>2005-08-01</date><risdate>2005</risdate><volume>56</volume><issue>2</issue><spage>360</spage><epage>364</epage><pages>360-364</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>Background/aims: The clearance of moxifloxacin is reported to be unaltered in the presence of renal insufficiency. There is little information about the clearance of intravenous moxifloxacin in renal replacement therapies during intensive care. The aim of this study was to determine the clearance of moxifloxacin during continuous veno-venous haemofiltration (CVVHF) in vitro. Methods: The elimination of moxifloxacin (reservoir with 600 mL of washed human erythrocytes, 100 mL of NaHCO3 and various amounts of Ringer solution and human albumin to give a total volume of 1000 mL, pH 7.35 ± 0.5; haematocrit 41 ± 2) during CVVHF in vitro with two filter conditions (during priming, after priming), three protein concentrations (human albumin: 0 g/L, 20 g/L, 40 g/L) and two filtration velocities [(i) standard condition: blood flow at 100 mL/min and turnover of 2 L/h; (ii) blood flow at 50 mL/min and turnover of 1 L/h] were investigated. Results: A new filter needs 20 min of priming before moxifloxacin reaches a steady relative filtration rate. The sieving coefficient with 0 g/L albumin was 1.07, with 20 g/L 0.90 and with 40 g/L 0.80. Under standard filtration conditions (i) the renal clearance was between 26.7 and 35.7 mL/min, and under the altered conditions (ii) it was 15.2 mL/min. Conclusion: During CVVHF in vitro we found filtration clearances of moxifloxacin of the same order as its renal clearance in healthy subjects. The high sieving coefficient, nearly independent of blood protein concentration, would suggest that moxifloxacin is filtered almost as freely as creatinine. These results do not indicate a need for dose adjustment under appropriate haemofiltration conditions and normal hepatic function.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>15983025</pmid><doi>10.1093/jac/dki205</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0305-7453 |
ispartof | Journal of antimicrobial chemotherapy, 2005-08, Vol.56 (2), p.360-364 |
issn | 0305-7453 1460-2091 |
language | eng |
recordid | cdi_proquest_miscellaneous_68431152 |
source | Oxford Journals Online |
subjects | Anti-Bacterial Agents - blood Anti-Bacterial Agents - pharmacokinetics antibiotics Antibiotics. Antiinfectious agents. Antiparasitic agents Area Under Curve artificial membranes Aza Compounds - blood Aza Compounds - pharmacokinetics Biological and medical sciences Culture Media dosage recommendations Erythrocytes - metabolism Fluoroquinolones Hemofiltration Humans In Vitro Techniques Medical sciences Metabolic Clearance Rate Models, Biological Pharmacology. Drug treatments Quinolines - blood Quinolines - pharmacokinetics renal failure renal replacement therapy |
title | Clearance of moxifloxacin during continuous haemofiltration (CVVHF) in vitro |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T10%3A42%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clearance%20of%20moxifloxacin%20during%20continuous%20haemofiltration%20(CVVHF)%20in%20vitro&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Ittner,%20K.%20P.&rft.date=2005-08-01&rft.volume=56&rft.issue=2&rft.spage=360&rft.epage=364&rft.pages=360-364&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/dki205&rft_dat=%3Cproquest_cross%3E886212371%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c416t-5a6c62e01b17fb6e4e9d21252fc12f1ac36a97e9a621bf2d439af28df255c1963%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=217669904&rft_id=info:pmid/15983025&rfr_iscdi=true |